MedPath

RUBIUS THERAPEUTICS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (100.0%)

RTX-224 Monotherapy in Patients With Solid Tumors

Phase 1
Terminated
Conditions
Non Small Cell Lung Cancer
Cutaneous Melanoma
Head and Neck Squamous Cell Carcinoma
Urothelial Carcinoma
TNBC - Triple-Negative Breast Cancer
Interventions
First Posted Date
2022-02-02
Last Posted Date
2022-12-09
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
7
Registration Number
NCT05219578
Locations
🇺🇸

HonorHealth, Scottsdale, Arizona, United States

🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

University of California San Francisco Health, San Francisco, California, United States

and more 2 locations

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Phase 1
Terminated
Conditions
Cervical Cancer
Head and Neck Cancer
Anal Cancer
Interventions
First Posted Date
2020-12-17
Last Posted Date
2022-12-08
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
9
Registration Number
NCT04672980
Locations
🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

The Angeles Clinic & Research Institute, Los Angeles, California, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

and more 7 locations

RTX-240 Monotherapy and in Combination With Pembrolizumab

Phase 1
Terminated
Conditions
Solid Tumor, AML Adult
Interventions
First Posted Date
2020-05-04
Last Posted Date
2022-12-13
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
69
Registration Number
NCT04372706
Locations
🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

The Angeles Clinic & Research Institute, Los Angeles, California, United States

🇺🇸

Sarah Cannon Research Institute/ Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 8 locations

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

Phase 1
Terminated
Conditions
Phenylketonurias
Interventions
First Posted Date
2019-10-01
Last Posted Date
2022-12-08
Lead Sponsor
Rubius Therapeutics
Target Recruit Count
1
Registration Number
NCT04110496
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.